SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Bill Wexler's Dog Pound
REFR 1.730+10.2%3:57 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (2216)7/15/1999 11:47:00 PM
From: BDR  Read Replies (1) of 10293
 
<TAP Holdings' Uprima, the only central nervous system drug for sexual dysfunction currently under development, expected to be on the market in the second half of 2000. A few months later, Zonagen (Nasdaq: ZONA - news)/Schering-Plough's (NYSE: SGP - news) Vasomax, already sold in some countries outside the United States, should join the group.>

Where does the Wall Street Transcript get the idea that Vasomax will ever get approved? And have they checked into those "sales" in other countries. Last I heard the number was very close to zero.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News